The purpose of this study was to determine the impact of expanding belzutifan access to VSP on time to first fill from treatment decision, number of gaps in therapy after initiation, and adherence. Patients who filled once VSP gained access to dispense belzutifan, initiated treatment more quickly, had fewer treatment gaps, and improved adherence compared to those who began treatment before VSP gained access to belzutifan. These findings support prior studies showing HSSPs outperform non-HSSPs

This quality improvement project evaluated a pharmacist driven lymphocyte monitoring dashboard for patients with multiple sclerosis (MS) on fumarates. The dashboard alerted pharmacists to 8 patients with lymphopenia in the month following implementation. All alerts resulted in chart review and pharmacist interventions were documented for 2 patients. Pharmacist survey responses demonstrated pharmacist satisfaction with the dashboard and an improved ability to monitor non-HSSP patients.

This study evaluated baseline symptoms and disease characteristics in pediatric patients prescribed dupilumab for EoE, factors affecting time to insurance approval, and pediatric patient response to dupilumab for EoE in the first year following dupilumab initiation. Median time to approval was 2 days versus 22 days if initially denied. Patients with dysphagia at baseline were less likely to be denied. Dupilumab demonstrated high rates of clinical, histological and endoscopic improvements.

Pharmacists play a vital role in specialty care, but intervention practices aren't standardized. This national survey of 24 health-system specialty pharmacies revealed wide variation in defining and documenting interventions, though most were pharmacist-led and recorded in EHRs. Standardizing these practices can improve care quality, highlight pharmacist impact, and strengthen patient outcomes.

This study evaluates health-system specialty pharmacy (HSSP) pharmacists' roles in medication discontinuations, switches, and dose changes, focusing on cost avoidance. HSSP pharmacists intervene to ensure safe and effective use of specialty medications, preventing unnecessary costs. Pharmacists successfully avoided $129,705 - $162,133 in direct costs through their interventions. These findings support the employment and role of pharmacists in HSSPs, extending beyond prescription filling.

This commentary provides practical recommendations for managing VMAT2 inhibitors. With limited clinical trial and real world data on this topic, the case examples and firsthand experience described are useful to clinicians and pharmacists who manage VMAT2 inhibitors.

This study describes differences in asthma-related clinical outcomes by race in patients initiating biologic therapy. There was a difference in clinic engagement between groups based on race. Cancellations were higher in patients that identify as White, and no shows were higher in patients that identify as Black or African American/Other. Identifying barriers that lead to reduced clinical engagement may allow for improved health in these patients.

This multisite national effort aims to identify measures deemed important and usable by specialty stakeholders that can be standardized and implemented in specialty pharmacy practice to ensure the safe, appropriate, and effective use of specialty medications in patients with RA. This poster describes the study methodology and response rate.

This prospective randomized study evaluated the implementation and effectiveness of using an electronic early treatment assessment and monitoring questionnaire for oral anticancer medication. The questionnaire was well received by pharmacists and patients. Patients who responded to the questionnaire were significantly more likely to have a pharmacist intervention related to adverse effects, demonstrating the effectiveness of using this technology tool for early monitoring.

This study evaluated the specialty pharmacist's role in medication access, treatment monitoring, and reducing maribavir waste. Pharmacists facilitated maribavir access by obtaining timely insurance prior authorizations (median = 1 day) and intervened to reduce 28 fills across 94 dispenses to avoid waste. Maribavir quantity was reduced in 10 dispenses during the final treatment course, based on CMV levels and time until next lab appointment, which resulted in $119,517 - $149,396 in avoided costs.